| Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel H Döhner, E Estey, D Grimwade, S Amadori, FR Appelbaum, T Büchner, ... Blood, The Journal of the American Society of Hematology 129 (4), 424-447, 2017 | 6244 | 2017 |
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, ... New England Journal of Medicine 377 (5), 454-464, 2017 | 2393 | 2017 |
| Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function L Chen, SN Willis, A Wei, BJ Smith, JI Fletcher, MG Hinds, PM Colman, ... Molecular cell 17 (3), 393-403, 2005 | 2289 | 2005 |
| Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England Journal of Medicine 383 (7), 617-629, 2020 | 2258 | 2020 |
| Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia H Kantarjian, A Stein, N Gökbuget, AK Fielding, AC Schuh, JM Ribera, ... New England Journal of Medicine 376 (9), 836-847, 2017 | 2048 | 2017 |
| Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN H Döhner, AH Wei, FR Appelbaum, C Craddock, CD DiNardo, H Dombret, ... Blood, The Journal of the American Society of Hematology 140 (12), 1345-1377, 2022 | 1911 | 2022 |
| Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia CD DiNardo, K Pratz, V Pullarkat, BA Jonas, M Arellano, PS Becker, ... Blood, The Journal of the American Society of Hematology 133 (1), 7-17, 2019 | 1830 | 2019 |
| International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022 | 1808 | 2022 |
| Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins SN Willis, L Chen, G Dewson, A Wei, E Naik, JI Fletcher, JM Adams, ... Genes & development 19 (11), 1294-1305, 2005 | 1624 | 2005 |
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized MF Van Delft, AH Wei, KD Mason, CJ Vandenberg, L Chen, PE Czabotar, ... Cancer cell 10 (5), 389-399, 2006 | 1488 | 2006 |
| The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models A Kotschy, Z Szlavik, J Murray, J Davidson, AL Maragno, ... Nature 538 (7626), 477-482, 2016 | 1099 | 2016 |
| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label … CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, ... The lancet oncology 19 (2), 216-228, 2018 | 761 | 2018 |
| Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial AH Wei, P Montesinos, V Ivanov, CD DiNardo, J Novak, K Laribi, I Kim, ... Blood, The Journal of the American Society of Hematology 135 (24), 2137-2145, 2020 | 698 | 2020 |
| Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study AH Wei, SA Strickland Jr, JZ Hou, W Fiedler, TL Lin, RB Walter, A Enjeti, ... Journal of Clinical Oncology 37 (15), 1277-1284, 2019 | 696 | 2019 |
| Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803, 2020 | 567 | 2020 |
| Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia SP Glaser, EF Lee, E Trounson, P Bouillet, A Wei, WD Fairlie, DJ Izon, ... Genes & development 26 (2), 120-125, 2012 | 474 | 2012 |
| AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies S Caenepeel, SP Brown, B Belmontes, G Moody, KS Keegan, D Chui, ... Cancer discovery 8 (12), 1582-1597, 2018 | 414 | 2018 |
| Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission AH Wei, H Döhner, C Pocock, P Montesinos, B Afanasyev, H Dombret, ... New England Journal of Medicine 383 (26), 2526-2537, 2020 | 391 | 2020 |
| MDM2 inhibition: an important step forward in cancer therapy M Konopleva, G Martinelli, N Daver, C Papayannidis, A Wei, B Higgins, ... Leukemia 34 (11), 2858-2874, 2020 | 320 | 2020 |
| BH3-mimetic drugs: blazing the trail for new cancer medicines D Merino, GL Kelly, G Lessene, AH Wei, AW Roberts, A Strasser Cancer cell 34 (6), 879-891, 2018 | 316 | 2018 |
Andrew W RobertsWalter and Eliza Hall Institute of Medical Research; Royal Melbourne HospitalVerified email at wehi.edu.au
